Please login to the form below

Not currently logged in
Email:
Password:

KaloBios names Herb Cross as CFO

He joins from Affymax

Herb Cross is to join KaloBios as the company's new chief financial officer.

After a transition period, he will succeed Jeffrey Cooper sometime in October or November, when Cooper is set to retire to spend more time with his family.

Cross joins from biopharma company Affymax, where he was also chief financial officer.

David Pritchard, president and CEO of KaloBios, described Cross as a “well respected finance professional with over sixteen years of experience”.

"His prior work in monoclonal antibody companies and his broad leadership roles in public companies will be invaluable to KaloBios as we focus on our next stage of growth and development,” added Pritchard.

This growth is being led by three drug development programmes for therapies to treat respiratory disorders and cancer.

This includes KB001-A, which is being developed in partnership with Sanofi for the treatment of Pseudomonas aeruginosa (Pa) infections as well as by KalaBios alone as cystic fibrosis treatment.

Cross said: "KaloBios has an interesting and diverse pipeline of monoclonal antibody therapeutic candidates in clinical development, in important areas of unmet medical need.” 

23rd September 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

World Mental Health Day 2019: Employment and Mental Illness
Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2019....
Changing direction
Changing direction: adapting to a rapidly-evolving environment
Chris Ross examines why creative partnerships could be key to commercial success in today’s healthcare marketplace...
customer journey
Understanding the patient journey
What we can learn from customer service...

Infographics